Mr. Herberts is a seasoned business leader with extensive experience in corporate strategy, commercialization and building cell & gene therapy companies. He most recently served as Senior Vice President and Chief Business Officer at Sangamo Therapeutics, where he led a number of corporate development transactions including global collaborations with Shire, Biogen and Pfizer. Herberts also led the team responsible for executing the recent $3 billion deal with Kite, a Gilead company, focused on genome editing of CAR-T cell therapies for oncology applications.